Cargando…

Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report

Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism....

Descripción completa

Detalles Bibliográficos
Autores principales: Naman, Annabelle, Delemer, Brigitte, Marot, Didier, Michelet, Elise, Decoudier, Bénédicte, Barraud, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239661/
https://www.ncbi.nlm.nih.gov/pubmed/35777000
http://dx.doi.org/10.1097/MD.0000000000029690
_version_ 1784737352512438272
author Naman, Annabelle
Delemer, Brigitte
Marot, Didier
Michelet, Elise
Decoudier, Bénédicte
Barraud, Sara
author_facet Naman, Annabelle
Delemer, Brigitte
Marot, Didier
Michelet, Elise
Decoudier, Bénédicte
Barraud, Sara
author_sort Naman, Annabelle
collection PubMed
description Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism. Intravenous or intramuscular treatment is then often necessary. We report the case of a patient with refractory hypothyroidism successfully treated with subcutaneous LT4. INTERVENTIONS AND OUTCOMES: After 4 weeks of weekly intravenous injections of 200 µg LT4 in complement to the oral treatment, thyroid balance was improved (TSH: 21.8 mIU/L). We tested the replacement of intravenous with subcutaneous injections of LT4 and gradually increased injection frequency from 1 to 3 injections per week (600 µg/week). Simultaneously, oral treatment was gradually tapered off, and within a few months, thyroid function tests were normalized. Two years later, hormone levels remained normal without symptoms of hypothyroidism. The only side effect was a local reaction in the first few weeks of injections, which spontaneously resolved. LESSONS: In this case of unexplained oral LT4 malabsorption, subcutaneous injection allowed a self-administrated physiological dose of LT4 3 times weekly. Considering the efficacy of subcutaneous injection of LT4, this treatment could be a safe and easy alternative for patients with malabsorption.
format Online
Article
Text
id pubmed-9239661
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-92396612022-06-30 Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report Naman, Annabelle Delemer, Brigitte Marot, Didier Michelet, Elise Decoudier, Bénédicte Barraud, Sara Medicine (Baltimore) Research Article Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism. Intravenous or intramuscular treatment is then often necessary. We report the case of a patient with refractory hypothyroidism successfully treated with subcutaneous LT4. INTERVENTIONS AND OUTCOMES: After 4 weeks of weekly intravenous injections of 200 µg LT4 in complement to the oral treatment, thyroid balance was improved (TSH: 21.8 mIU/L). We tested the replacement of intravenous with subcutaneous injections of LT4 and gradually increased injection frequency from 1 to 3 injections per week (600 µg/week). Simultaneously, oral treatment was gradually tapered off, and within a few months, thyroid function tests were normalized. Two years later, hormone levels remained normal without symptoms of hypothyroidism. The only side effect was a local reaction in the first few weeks of injections, which spontaneously resolved. LESSONS: In this case of unexplained oral LT4 malabsorption, subcutaneous injection allowed a self-administrated physiological dose of LT4 3 times weekly. Considering the efficacy of subcutaneous injection of LT4, this treatment could be a safe and easy alternative for patients with malabsorption. Lippincott Williams & Wilkins 2022-06-30 /pmc/articles/PMC9239661/ /pubmed/35777000 http://dx.doi.org/10.1097/MD.0000000000029690 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Naman, Annabelle
Delemer, Brigitte
Marot, Didier
Michelet, Elise
Decoudier, Bénédicte
Barraud, Sara
Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title_full Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title_fullStr Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title_full_unstemmed Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title_short Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
title_sort efficacy of subcutaneous levothyroxine in a case of refractory hypothyroidism: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239661/
https://www.ncbi.nlm.nih.gov/pubmed/35777000
http://dx.doi.org/10.1097/MD.0000000000029690
work_keys_str_mv AT namanannabelle efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport
AT delemerbrigitte efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport
AT marotdidier efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport
AT micheletelise efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport
AT decoudierbenedicte efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport
AT barraudsara efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport